LPCN Lipocine Inc.

3.78
-0.05  -1.31%
Previous Close 3.83
Open 3.83
Price To book 2.50
Market Cap 69.02M
Shares 18,260,000
Volume 79,281
Short Ratio 16.77
Av. Daily Volume 127,381

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. Intends to meet FDA to discuss Phase 3 plans.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Dosing flexibility trial to be initiated 1Q 2017 with data due in 2Q 2017.
LPCN 1021
Men with low testosterone (Low T)
Phase 3 protocol to be filed with FDA 1H 2017.
LPCN 1107
Prevention of preterm birth ("PTB").

Latest News

  1. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
  3. LIPOCINE INC. Files SEC form 8-K, Change in Directors or Principal Officers
  4. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  5. Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
  6. LPCN: Early Start to Tlando Validation Trial
  7. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  8. Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate
  9. Lipocine, Inc. :LPCN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 6, 2016
  10. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  11. Lipocine to Initiate Dosing Validation Study for LPCN 1021, Oral Testosterone Replacement Product Candidate
  12. LPCN Gets Lean Guiding Tlando Through Approval Process.
  13. LIPOCINE INC. Financials
  14. LIPOCINE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial
  15. LIPOCINE INC. Files SEC form 10-Q, Quarterly Report
  16. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  17. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  18. Testosterone Ruling Gives Boost to Lipocine (LPCN)
  19. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  20. Here’s Why Lipocine Inc. (LPCN), Zillow Group Inc. (ZG) and Three Other Stocks Are Gaining Ground Today